Program Schedule

64
HIV Antiretroviral Therapy

Thursday, October 9, 2014: 2:00 PM-3:45 PM
Room: The Pennsylvania Convention Center: 107-AB

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Health care workers, HIV clinicians, HIV specialists, Infection preventionists, Infectious diseases physicians, Members-in-training, Public health practitioners

Tracks: Adult ID, Epidemiology and Infection Control, Global ID, HIV-STD-TB

Moderators:  David Wohl, MD, University of North Carolina and Judith Aberg, MD, FIDSA, Icahn School of Medicine at Mount Sinai

Presentations:
2:00 PM
536
Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs) Comparing Initial Non-Nucleoside Reverse-Transcriptase Inhibitor (NNRTI)- versus Ritonavir Boosted Protease Inhibitor (PI/r)-based Anti-Retroviral Therapy (ART)
Álvaro H Borges, MD, MSc ; Andreas Lundh, MD, MSc, PhD ; Britta Tendal, PhD ; Tania B Huedo-Medina, PhD ; John a Bartlett, MD ; Dominique Costagliola, PhD ; Nathan Clumeck, MD ; Eric S Daar, MD ; Edwin Dejesus, MD, FACP. FIDSA ; Patricia Echeverría, MD ; Magnus Gisslén, MD, PhD ; Miwako Honda, MD ; Michael Hughes, Ph.D. ; P Khabo, PhD ; Stephanus Komati, MD, PhD ; Princy N. Kumar, MD ; Shahin Lockman, MD, MSc ; Rodger Macarthur, MD ; Franco Maggiolo, MD, PhD ; Alberto Matteelli, MD ; José M Miró, MD ; Rebekah L Puls, MD, PhD ; Sharon Riddler, MD, MPH ; Paul Sax, MD, FIDSA ; Juan Sierra-Madero, MD ; Carlo Torti, MD ; Jens Lundgren, MD, D.M.Sc., Professor
2:15 PM
537
STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has Similar Efficacy and is Well-Tolerated Compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96
Catherine Creticos, MD ; Cynthia Brinson ; Cheryl Mcdonald, MD ; Sorana Segal-Maurer, MD ; Indira Brar, MD ; Barbara Wade ; Will Garner, PhD ; Danielle Porter ; Shampa De-Oertel, PhD ; Amy Weinberg, NP ; Toni Sparrow
2:30 PM
538
A Retrospective Study to Evaluate the Safety of Switching Antiretroviral Therapy (ART) to Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) STR in Virologically Suppressed HIV-Infected Patients
Ana Monczor, MD ; Xiaoying Yu, MD, MS ; Karen J. Vigil, MD ; Claudia Kozinetz, PhD, MPH ; Roberto Arduino, MD
2:45 PM
539
Peer-led intervention to address non-adherence among adults linked to HIV medical care but failing treatment
David Mckinsey, MD ; Maithe Enriquez, PhD ; An-Lin Cheng, PhD
3:00 PM
540
HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis
Cynthia Brinson ; Jacob Lalezari ; Gulam H Latiff ; Melanie Thompson, MD ; Juan Echevarría ; Sandra Treviño-Pérez ; David Stock ; Samit R Joshi ; George J Hanna ; Max Lataillade
3:15 PM
541
HIV Rebound Kinetics and CD4+ T-Cell Loss after Treatment Interruption: A Pooled Analysis of Six AIDS Clinical Trials Group (ACTG) Studies
Jonathan Li, MD, MMSc ; Evgenia Aga, MS ; Ronald Bosch, PhD ; John Mellors, MD ; Daniel Kuritzkes, MD, FIDSA ; Michael Para, MD ; Rajesh Gandhi, MD
3:30 PM
542
A Unique Non-Nucleoside RT Inhibitor Resistance Mutation in Epidemic Russian Subtype A HIV-1 Strains
Anna Kolomeets, MD/Ph.D ; Robert Shafer, MD

CME Credits:

ACPE Credits:

ACPE Number:

Disclosures:

D. Wohl, Gilead: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient
Janssen: Scientific Advisor, Consulting fee
Merck: Grant Investigator, Grant recipient
ViiV: Grant Investigator, Grant recipient

J. Aberg, Merck: Scientific Advisor, Consulting fee
Janssen: Scientific Advisor, Consulting fee
AbbVie: Scientific Advisor, Consulting fee
Amgen: Scientific Advisor, Consulting fee

See more of: Oral Abstract Session
<< Previous Session | Next Session >>

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek